http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김용주,임수혁,이호신,황성도,Kim, Yong-Joo,Im, Soo-Hyok,Lee, David,Hwang, Sung-Do Korean Society of Road Engineers 2008 한국도로학회논문집 Vol.10 No.4
To produce asphalt mixtures at temperature significantly below $135^{\circ}C$, called "Warm Mix Asphalt (WMA)", new technologies are currently being developed worldwide. To produce WMA mixtures in this research, foaming technology is adopted to effectively disperse asphalt binder at lower temperature than hot mix asphalt (HMA) in the field. The main objectives of this study are to develop WMA process using foaming technology (WMA-foam) and evaluate its performance characteristics under various temperatures and loading conditions. WMA-foam mixtures were produced by injecting PO 64-22 foamed asphalt into warm aggregates whereas WMA mixtures were produced by adding PO 64-22 asphalt (without foaming) in the warm aggregates. Both dynamic modulus and flow number of WMA-foam mixtures were higher than those of WMA mixtures. Based on the limited dynamic modulus and repeated load test results, it is concluded that the WMA-foam mixtures using warm aggregates at $100^{\circ}C$ are more resistant to fatigue cracking and rutting than WMA mixtures. 최근에 $135^{\circ}C^{\circ}C$ 이하의 온도에서 생산되는 중온형 아스팔트 혼합물의 새로운 생산 기술이 전세계적으로 개발되고 있다. 본 연구에서는 가열 아스팔트보다 낮은 온도에서 아스팔트를 효과적으로 골재에 분산시켜 코팅할 수 있는 폼드 아스팔트 기술을 이용하여 중온형 아스팔트 혼합물을 생산하였으며, 최근 개발된 새로운 Simple Performance Testing 장비를 이용하여 다양한 온도와 하중조건 하에서 중온형 폼드 아스팔트 혼합물의 공용성 특성을 평가하였다. 중온형 폼드 아스팔트 혼합물은 FG 64-22의 아스팔트를 거품상태로 만들어 중온으로 가열된 골재에 뿌려서 제조하였으며, 중온형 아스팔트 혼합물은 중온의 골재에 FG 64-22의 아스팔트를 액상 상태로 첨가하여 제조하였다. 중온형 폼드 아스팔트 혼합물은 중온형 아스팔트 혼합물보다 높은 동탄성계수와 Flow Number를 나타내었다. 따라서, $100^{\circ}C$로 가열된 골재를 사용하여 생산된 중온형 폼드 아스팔트 혼합물은 중온형 아스팔트 혼합물에 비하여 피로균열 및 소성변형 저항에 우수한 것으로 평가되었다.
김용주,이호신,임수혁 한국도로학회 2011 한국도로학회논문집 Vol.13 No.2
The practice of asphalt pavement recycling has grown rapidly over the decade, one of which is the cold in-place recycling with the foamed asphalt (CIR-foam) or the emulsified asphalt (CIR-emulsion). Particularly, in Iowa, the CIR has been widely used in rehabilitating the rural highways because it significantly increases the service life of the existing pavement. The CIR layer is typically overlaid by the hot mix asphalt (HMA) to protect it from water ingress and traffic load and obtain the required pavement structure and texture. Most public agencies have different curing requirements based on the number of curing days or the maximum moisture contents for the CIR before placing the overlay. The main objective of this study is to develop a moisture loss index that the public agency can use to monitor the moisture content of CIR layers in preparation for a timely placement of the wearing surface. First, the moisture contents were measured in the field using a portable time domain reflectometry (TDR) device. Second, the weather information in terms of rain fall, air temperature, humidity and wind speed was collected from the same location. Finally, a moisture loss index was developed as a function of initial moisture content, air temperature, humidity and wind speed. The developed moisture loss index based on the field measurements would help the public agency to determine an optimum timing of an overlay placement without continually measuring moisture conditions in the field.
김형준,황인철,염창환,안홍엽,최윤선,이재준,임수혁,Kim, Hyung Jun,Hwang, In Cheol,Yeom, Chang Hwan,Ahn, Hong Yup,Choi, Youn Seon,Lee, Jae Jun,Lim, Su Hyuk 한국호스피스완화의료학회 2014 한국호스피스.완화의료학회지 Vol.17 No.4
목적: 혈청 비타민 C 수치는 체내 항산화상태를 나타내는 지표로서, 암환자에서는 정상인에 비해 감소되어 있다. 하지만, 이 지표가 말기암환자에서 어느 정도 감소되어 있고, 그 감소에 어떤 요인들이 관련되는지에 대한 연구는 매우 드물다. 방법: 두 개 기관의 완화의료병동에 입원했던 암환자 65명을 대상으로 하였다. 환자의 나이, 성별, 암의 종류, 기능상태, 임상증상, 완치 목적의 암 치료력, 그리고 혈청 비타민 C를 포함한 혈액검사 자료를 수집하였다. 혈청 비타민 C 수치의 사분위수를 기준으로 두 군(3사분위수 이하 vs. 4 사분위수)으로 분류한 후 각 군의 차이를 비교하였고, 단계적 다중 로지스틱 회귀분석을 통해 혈청 비타민 C 수치와 관련된 인자를 확인하였다. 결과: 대상자의 혈청 비타민 C의 평균은 $0.44{\mu}g/mL$이었으며, 대상자 전체가 비타민 C 결핍에 해당되었다. 단변량 분석에서는, 비폐암 환자이거나(P=0.041) 발열이 있는 환자(P=0.034)에서 낮은 혈청 비타민 C 수치를 보였다. 폐암, 발열, 삼킴곤란, 호흡곤란, C 반응단백, 그리고 항암화학요법 등의 잠재적인 인자들을 보정한 다변량 분석에서, 낮은 혈청 비타민 C 수치를 나타낼 가능성은 항암화학요법을 받은 군에서 그렇지 않은 군에 비해 3.7배 높았고(P=0.046), 발열이 있는 군에서 그렇지 않은 군에 비해 7.22배 높았다(P=0.020). 결론: 말기암환자에서 비타민 C 부족은 매우 심각하였고, 항암화학요법 치료력과 발열이 관련 있었다. Purpose: Serum vitamin C is one of the indicators for antioxidant levels in the body and it is lower in cancer patients compared with the healthy population. However, there have been few studies on the levels of serum vitamin C in terminally ill cancer patients and related factors. Methods: We followed 65 terminal cancer patients who were hospitalized in two palliative care units. We collected data of age, sex, cancer type, functional status, clinical symptoms, history of cancer therapy, and various laboratory findings including serum vitamin C level. Patients were categorized into two groups according to the quartile of serum vitamin C level (Q1-3 vs. Q4), which were compared each other. Stepwise multiple logistic regression analysis was used to identify factors related to serum vitamin C levels. Results: The mean serum vitamin C level was $0.44{\mu}g/mL$, and all patients fell into the category of vitamin C deficiency. Univariate analysis showed that The serum vitamin C level was lower in non-lung cancer patients (P=0.041) and febrile patients (P=0.034). Multivariate analysis adjusted for potential confounders such as lung cancer, fever, dysphagia, dyspnea, C reactive protein, and history of chemotherapy demonstrated that odds for low serum vitamin C level was 3.7 for patients receiving chemotherapy (P=0.046) and 7.22 for febrile patients (P=0.02). Conclusion: Vitamin C deficiency was very severe in terminally ill cancer patients, and it was associated with history of chemotherapy and fever.
여성형탈모에서 두타스테리드의 임상적 치료 효과 및 작용 기전에 대한 연구
김수정 ( Soo Jung Kim ),황율례 ( Yul-lye Hwang ),임수혁 ( Su-hyuk Yim ),홍동균 ( Dong Kyun Hong ),최종원 ( Chong Won Choi ),정경은 ( Kyung Eun Jung ),서영준 ( Young-joon Seo ),김창덕 ( Chang-deok Kim ),신정민 ( Jung Min Shin ) 대한피부과학회 2020 대한피부과학회지 Vol.58 No.4
Background: Female-pattern hair loss (FPHL) is a common hair loss disorder in women. The various treatments include topical minoxidil and 17α-estradiol, as well as oral anti-androgens. However, the clinical efficacy of 5α -reductase inhibitors remains controversial. Objective: We evaluated the clinical utility of dutasteride in FPHL patients and how dutasteride promotes hair growth. Methods: We evaluated hair follicle density and thickness before and after oral dutasteride treatment in 24 patients with FPHL. We measured β-catenin activity in primary cultures of human dermal papilla cells (DPCs) using the TOP Flash reporter assay and Western blotting. The expression levels of genes promoting hair growth were quantitatively assessed using quantitative polymerase chain reaction (Q-PCR). Results: The mean vertex hair density increased significantly from 67±14 to 76±13/cm<sup>2</sup> (p=0.001) and the mean occipital hair density increased from 89±11 to 94±13/cm<sup>2</sup> (p=0.012) after dutasteride treatment. However, the mean hair thickness did not increase. When DPCs were treated with dutasteride, TOP Flash activity increased in a dose-dependent manner, and the protein level of non-phosphorylated (active) β-catenin also increased. The mRNA level of vascular endothelial growth factor increased, but the mRNA levels of the keratinocyte growth factor, insulin growth factor-1, and Noggin were not affected by dutasteride. Conclusion: This study shows a novel mechanism of dutasteride in promoting hair growth and provides support for the possible clinical application of 5α-reductase inhibitors for the treatment of FPHL. (Korean J Dermatol 2020;58(4):231∼238)